AZEDRA
Total Payments
$860,997
Transactions
108
Doctors
42
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $275,551 | 8 | 1 |
| 2023 | $138,532 | 24 | 12 |
| 2022 | $77,871 | 44 | 31 |
| 2021 | $60,494 | 10 | 4 |
| 2020 | $40,304 | 12 | 7 |
| 2019 | $268,245 | 10 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $720,296 | 28 | 83.7% |
| Consulting Fee | $102,298 | 24 | 11.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,508 | 8 | 2.0% |
| Grant | $10,000 | 1 | 1.2% |
| Space rental or facility fees (teaching hospital only) | $4,000 | 3 | 0.5% |
| Travel and Lodging | $2,935 | 4 | 0.3% |
| Education | $2,550 | 3 | 0.3% |
| Food and Beverage | $1,411 | 37 | 0.2% |
Payments by Type
Research
$720,296
28 transactions
General
$140,701
80 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN OBSERVATIONAL STUDY TO ASSESS THE RISK OF SECONDARY MALIGNACIES FOLLOWING TREATMENT WITH AZEDRA | PROGENICS PHARMACEUTICALS, INC. | $275,213 | 0 |
| MIP-IB12B-EAP | Progenics Pharmaceuticals, Inc. | $239,654 | 0 |
| AN OBSERVATIONAL STUDY TO ASSESS THE RISK OF SECONDARY MALIGNACIES FOLLOWING TREATMENT WITH AZEDRA | Progenics Pharmaceuticals, Inc. | $188,440 | 0 |
| A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma | Progenics Pharmaceuticals, Inc. | $10,668 | 0 |
| MIP-IB12B | Progenics Pharmaceuticals, Inc. | $6,321 | 0 |
Top Doctors Receiving Payments for AZEDRA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Philadelphia, PA | $736,846 | 35 |
| , MD | Neurology | West Hempstead, NY | $64,100 | 8 |
| , M.D., PH.D | Nuclear Medicine | Portland, OR | $15,925 | 4 |
| , M.D | Endocrinology, Diabetes & Metabolism | Houston, TX | $5,911 | 6 |
| , MD | Medical Oncology | Columbus, OH | $4,590 | 2 |
| , MD | Specialist | Philadelphia, PA | $4,340 | 1 |
| , MD, PHD | Endocrinology, Diabetes & Metabolism | Aurora, CO | $3,450 | 2 |
| , MD | Nuclear Medicine | New York, NY | $2,813 | 4 |
| , MD | Medical Oncology | Houston, TX | $2,300 | 1 |
| Chih-Yi Liao | Hematology & Oncology | Chicago, IL | $2,226 | 3 |
| , M.D | Internal Medicine | Rochester, MN | $2,186 | 2 |
| , D.O | Endocrinology, Diabetes & Metabolism | Dallas, TX | $2,169 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Ann Arbor, MI | $2,075 | 2 |
| Kimberly Perez | Hematology | Providence, RI | $1,980 | 1 |
| , M.D., PH.D | Medical Oncology | New York, NY | $1,888 | 1 |
| , MD | Surgery | Cleveland, OH | $1,843 | 2 |
| , M.D | Endocrinology, Diabetes & Metabolism | Los Angeles, CA | $1,842 | 1 |
| , MD | Internal Medicine | Iowa City, IA | $1,842 | 1 |
| , M.D | Hematology & Oncology | New York, NY | $1,750 | 2 |
| , MD | Medical Oncology | San Diego, CA | $337.50 | 1 |
| , MD | Internal Medicine | Hershey, PA | $62.99 | 1 |
| , MD, PHD | Endocrinology, Diabetes & Metabolism | Chicago, IL | $58.05 | 1 |
| , MD | Radiation Oncology | Cheektowaga, NY | $32.68 | 2 |
| , M.D | Radiation Oncology | Cheektowaga, NY | $32.68 | 2 |
| , PA-C | Physician Assistant | Cheektowaga, NY | $32.67 | 2 |
Ad
Manufacturing Companies
- Progenics Pharmaceuticals, Inc. $585,446
- PROGENICS PHARMACEUTICALS, INC. $275,551
Product Information
- Type Drug
- Total Payments $860,997
- Total Doctors 42
- Transactions 108
About AZEDRA
AZEDRA is a drug associated with $860,997 in payments to 42 healthcare providers, recorded across 108 transactions in the CMS Open Payments database. The primary manufacturer is Progenics Pharmaceuticals, Inc..
Payment data is available from 2019 to 2024. In 2024, $275,551 was paid across 8 transactions to 1 doctors.
The most common payment nature for AZEDRA is "Unspecified" ($720,296, 83.7% of total).
AZEDRA is associated with 5 research studies, including "AN OBSERVATIONAL STUDY TO ASSESS THE RISK OF SECONDARY MALIGNACIES FOLLOWING TREATMENT WITH AZEDRA" ($275,213).